Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 29, 2024
Treatment adjustment in biologic therapies for moderate-to-severe plaque psoriasis: a German retrospective chart review (TABU)
Natalia Kirsten, Simone Rubant, Susana Gomis-Kleindienst, et al.
The Journal of Dermatological Treatment
|
July 15, 2022
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
Bruce Strober, April Armstrong, Simone Rubant, et al.
Experimental Dermatology
|
May 29, 2010
Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1
Anne Dudeck, Mandy Leist, Simone Rubant, et al.
Biochemical Pharmacology
|
June 20, 2006
The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity
Juliane Fritzsche, Susanne Alban, Ralf J Ludwig, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Alan Menter, Diamant Thaçi, Kim A Papp, et al.
Experimental Dermatology
|
July 18, 2006
Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo
Simone Rubant, Ralf J Ludwig, Jeannette Pfeffer, et al.
Frontiers in Immunology
|
June 7, 2024
Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries
Liisi Raam, Ilona Hartmane, Skaidra Valiukevičienė, et al.
The Journal of Biological Chemistry
|
September 27, 2008
Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation
Margarethe Müller, Kirill Essin, Kerstin Hill, et al.
Dermatology and Therapy
|
January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
Dermatology and Therapy
|
February 5, 2025
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 29, 2024
Treatment adjustment in biologic therapies for moderate-to-severe plaque psoriasis: a German retrospective chart review (TABU)
Natalia Kirsten, Simone Rubant, Susana Gomis-Kleindienst, et al.
The Journal of Dermatological Treatment
|
July 15, 2022
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
Bruce Strober, April Armstrong, Simone Rubant, et al.
Experimental Dermatology
|
May 29, 2010
Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1
Anne Dudeck, Mandy Leist, Simone Rubant, et al.
Biochemical Pharmacology
|
June 20, 2006
The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity
Juliane Fritzsche, Susanne Alban, Ralf J Ludwig, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Alan Menter, Diamant Thaçi, Kim A Papp, et al.
Experimental Dermatology
|
July 18, 2006
Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo
Simone Rubant, Ralf J Ludwig, Jeannette Pfeffer, et al.
Frontiers in Immunology
|
June 7, 2024
Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries
Liisi Raam, Ilona Hartmane, Skaidra Valiukevičienė, et al.
The Journal of Biological Chemistry
|
September 27, 2008
Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation
Margarethe Müller, Kirill Essin, Kerstin Hill, et al.
Dermatology and Therapy
|
January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
Dermatology and Therapy
|
February 5, 2025
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, et al.
Page
of 2